Aarti Drugs Q2 Profit Jumps 83%, Gross Margins Hit 39.9% on API Recovery

The Quick Take

• Aarti Drugs Q2 net profit jumped 83% YoY; shares responded with a 7% intraday gain.
• Gross profit rose 35% to ₹329.7 crore, with gross margins expanding 240 bps to 39.9% from 37.5% — indicating improved pricing power and product mix.
• The pharma company's earnings trajectory reflects broad tailwinds in India's active pharmaceutical ingredient (API) sector.

Aarti Drugs' Q2 FY27 results confirm an ongoing earnings upgrade cycle in the Indian pharma API space. The 240-basis-point margin expansion signals that input cost normalisation — particularly in key chemical intermediates — is flowing through to profitability. With gross margins pushing toward 40%, Aarti is recapturing the efficiency levels seen before the pandemic-era supply-chain disruptions that compressed margins across the sector.

The 83% profit surge is partly a low base effect from a weaker Q2 FY26, but the absolute margin improvement adds credibility to the growth narrative. Aarti Drugs is a mid-cap API manufacturer supplying to both Indian and export markets; sustained margin gains suggest it is benefiting from both volume recovery and the ongoing China+1 sourcing shift by global pharma companies.

Investors will watch whether Q3 FY27 sustains these margins or whether a one-time benefit inflated Q2 numbers. The key metrics to track are raw material cost trends and revenue split between domestic and regulated export markets (US/Europe), which carry higher margins and are the growth engines for Indian API companies over the next 3-5 years.

Synthesized from 1 source.